Zhang Wei, Davidson Jonathan Rt
Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, Durham, NC 27710, USA.
Expert Opin Pharmacother. 2007 Aug;8(12):1861-70. doi: 10.1517/14656566.8.12.1861.
Post-traumatic stress disorder (PTSD) is often a chronic and disabling anxiety disorder that develops after exposure to a traumatic event. Researchers have demonstrated efficacy for both pharmacologic and psychosocial interventions in the treatment of PTSD. First-line pharmacotherapeutic options are the selective serotonin re-uptake inhibitors and serotonin noradrenaline re-uptake inhibitors. Older antidepressant agents, such as the tricyclic antidepressants and the monoamine oxidase inhibitor, phenelzine, have also proven efficacy in PTSD among more established agents. However, concerns for side effects have limited frequent use of these. Existing pharmacologic agents produce meaningful results and bear the advantage of treating depression and other co-morbid disorders, yet still fall short of being ideal due to limited response and remission rates and tolerability issues. The need for improving pharmacotherapy of PTSD remains compelling and directions for further research are discussed.
创伤后应激障碍（PTSD）通常是一种慢性致残性焦虑障碍，在经历创伤性事件后发病。研究人员已证明药物和心理社会干预在治疗PTSD方面均有效。一线药物治疗选择是选择性5-羟色胺再摄取抑制剂和5-羟色胺去甲肾上腺素再摄取抑制剂。较老的抗抑郁药，如三环类抗抑郁药和单胺氧化酶抑制剂苯乙肼，在更成熟的药物中也已证明对PTSD有效。然而，对副作用的担忧限制了这些药物的频繁使用。现有的药物制剂产生了有意义的结果，具有治疗抑郁症和其他共病的优势，但由于反应率、缓解率有限以及耐受性问题，仍未达到理想状态。改善PTSD药物治疗的需求仍然迫切，本文将讨论进一步研究的方向。
